Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | USP10 | Q14694 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20531809 | 0.93 | KMT2A (0.36) | KMT2AMEN1LMNAMAPK1MAPT | |
| SCHEMBL18312806 | 0.93 | KMT2A (0.36) | KMT2AMEN1LMNAMAPK1MAPT | |
| SCHEMBL18312736 | 0.93 | KMT2A (0.36) | KMT2AMEN1LMNAMAPK1MAPT | |
| SCHEMBL22591747 | 0.91 | KMT2A (0.35) | KMT2AMEN1LMNAMAPK1MAPT | |
| SCHEMBL20531853 | 0.89 | KMT2A (0.35) | KMT2AMEN1LMNAMAPK1MAPT | |
| SCHEMBL18313336 | 0.89 | KMT2A (0.35) | KMT2AMEN1LMNAMAPK1MAPT | |
| SCHEMBL18313337 | 0.89 | KMT2A (0.35) | KMT2AMEN1LMNAMAPK1MAPT | |
| SCHEMBL29979932 | 0.89 | KDM4E (0.34) | KMT2AMEN1LMNAMAPK1KDM4E | |
| SCHEMBL19986870 | 0.89 | KDM4E (0.34) | KMT2AMEN1LMNAMAPK1KDM4E | |
| SCHEMBL19974018 | 0.89 | PDE4A (0.36) | KMT2AMEN1LMNAMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-18 | — | — | US | disclosed |
| CN-109689656-B | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-24 | — | — | US | disclosed |
| EP-3512849-B1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | BAYER AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3512849-B1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | BAYER AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| EP-3512849-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050510-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050510-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | KMT2A 2845/4885MEN1 3502/4885LMNA 310/4885 |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | KMT2A 2845/4885MEN1 3502/4885LMNA 310/4885 |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | KMT2A 2845/4885MEN1 3502/4885LMNA 310/4885 |
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | KMT2A 2845/4885MEN1 3502/4885LMNA 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.